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Extracellular perfusion with the antihypertensive agent cromakalim produced an inhibition of 2266% in the low-threshold transient Ca*+ (T-like) 
current in NGIW15 hybrid cells. Cromakalim suppressed the ~gh-t~old and long-lasting Ba2+ current (L-like CaZ+ current) by 2973%, but 
had almost no effect on the hip-th~shold and inactivating B3+ current (N-like CaZ+ current). IC, for T-like and L-like currents was the same 
at about 100 PM. The inhibitory effect developed relatively fast and was reversible. These results indicate that cromakalim can selectively inhibit 
the activity of inward Ca*+ currents. 
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1. INTRODUCTION 
Cromakalim (BRL 38227: (-)-~~~~~“~yano-3,4- 
dihydro-2, 2-dimethyl-4-(2-oxo- I-pyrrolidinyl)-2H-l- 
benzo-[blpyran-3-011) is a novel class of antihyper- 
tensive drugs which cause relaxation in smooth muscle 
preparations [l]. The principal site of action of 
cromakalim is thought to be K+ channels [2]: stimula- 
tion of the opening of ATP-sensitive K+ channels [3,4], 
leading to cell membrane hyperpolarization. In addi- 
tion, it has recently been reported that cromakalim has 
a direct effect on inward Ca2+ currents in smooth mus- 
cle cells of the rat portal vein [5]. Ca2+ channels are sub- 
divided into 3 distinct types, namely T-, N-, and L-types 
originally reported in sensory ganglion cells 161. The 
low-threshold and transient (T-type) current and the 
high-threshold Ca” currents consist of the inactivating 
(N-type) current and the non-inactivating (L-type) cur- 
rent. The N-type Ca2+ current has not been found in 
muscle cells of the vascmar system but has been record- 
ed in neuronal cells 171. NG108-15 neuroblastoma x 
glioma hybrid cells, neuronal model cells [8], have been 
reported to possess two types of Ca2’ (T- and L-like) 
currents [9]. Recently Docherty and McFadzean found 
a rapidly inactivating (N-like) component of the high- 
threshold Ca2’ current in NG108-15 cells [lo]. 
Therefore, it is worth examining NG108-15 cells to find 
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out to which species of Ca2+ currents cromakalim is 
sensitive. In this report we show that cromakalim in- 
hibits the T- and L-like Ca” currents without any effect 
on the N-like current of NG108-15 cells under the 
voltage-clamp condition. 
2. MATERIALS AND METHODS 
Cells used in these experiments were NGlOB-15 mouse neuro- 
blastoma x rat glioma hybrid cells. Hybrid cells were cultured in 
polyornithine-coated ishes and induced to differentiate by growing 
in Dulbecco’s modified Eagle’s medium containing 1% fetal bovine 
serum, 100 FM hypoxanthine, 16 PM thymidine and 0.25 mM 
dibutyryl cyclic AMP for 2-3 weeks, as described previously 1111. 
Membrane currents were recorded via a continuous singfe- 
electrode voltage-clamp amplifier (model 2A, Axon Instruments) in a 
switching mode operating at 2-6 KHz. For the low-threshold Ca*’ (T- 
like) current, membrane currents were measured with sharp 
microelectrodes (filled with 1 M K” citrate, 10 r110) by impaling cells 
soaked in Tris-HCl-buffered saline (TBS) (in mM): NaCl 140, KC1 
5.4, CaClz 1.8, MgClz 0.8, D-glucose 20, tetrodotoxin 0.5 FM, Tris- 
HCI 20, pH 7.2. The patch voltage-clamp technique was applied to 
the recording of high-threshold Ca2+ (N- and L-like) currents, with 
Ba’+ as ion charge carrier in the following extracellular solution (in 
mM): Bach 50, NaCl30, MgClz 1, CsCl5, glucose 20, tetraethylam- 
monium chloride 20, tetrodotoxin 1 AM; Hepes 10; pH 7.24 as 
described [9]. The patch electrodes contained a solution of the follow- 
ing composition (in mM): CsCl 150, MgClz 1, EGTA 10, ATP 1, 
Hepes 10, pH 7.3. Cromakalim was dissolved to make a stock solu- 
tion (50 mM) in 100% dimethyl sulfoxide (DMSG). Cells were super- 
fused at 33-3S°C with the buffer solution plus 1% DMSO with or 
without cromakalim. In order to exclude artifacts of the solvent, con- 
trol experiments were carried out with cromakalim in 0.1% ethanol 
solution. Results obtained with the two solvents were identical, and 
DMSO alone did not mimic the effect of cromakalim. Cromakahm 
was a kind gift from Beecham Ph~maceutic~s, Harlow, UK. 
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Fig. 1. Effects of cromakalim on low-threshold transient calcium cur- 
rents of NG108-15 cells. A. Ca*+ inward currents elicited in one cell, 
by going from a holding potential of - 80 mV to a test potential of 
-40 mV before (0) and during (0) application of 500 ,uM 
cromakalim. B. Current-voltage plot of Ca*+ currents at peak before, 
during, and after cromakalim, as indicated. 
3. RESULTS AND DISCUSSION 
We examined the effects of cromakalim on 3 classes 
of Ca*+ currents in NG108-15 cells. First, the effect of 
cromakalim was studied on the transient inward Ca*+ 
current (the T-component). 
In a typical voltage-clamp experiment, the cells were 
subjected to 0.3 s depolarizing voltage steps (to -40 
mV) from a holding potential of - 80 mV in the 
presence of 0.5 /IM tetrodotoxin. As illustrated in 
fig.lA, such voltage steps evoked a fast transient in- 
ward current followed by a sustained outward current. 
Cromakalim caused a decrease in the inward current of 
42 +- 5% (n = lo), as well as in the outward current, 
but had no effect on the resting current at - 80 mV. The 
inhibition in the transient inward Ca*+ current 
amplitude caused by cromakalim occurred at all poten- 
tials tested as shown in the current-voltage relation- 
ships (fig. 1B). 
The whole cell patch-clamp recording from NGlOS- 
15 cells perfused with 50 mM BaCl2 revealed two types 
of Ba*+ currents that are due to activation of Ca*+ 
channels by depolarization steps. Usually in hybrid cells 
depolarized to 0-+ 10 mV from a holding potential of 
- 80 mV, this current was maximal immediately after a 
voltage step (the N-like current) and was inactivated 
progressively thereafter (fig.2A). The degree of such in- 
activation varied among cells (58 + 5% inactivation 
after 1 s, mean + SEM, n = 25), and the long-lasting 
current remained active at the end of the 1 s depo- 
larizing step (the L-like current). Cromakalim (100-500 
PM) reduced the long-lasting current by 55 + 4% 
(n = 12), although little or no effect was found in the 
peak current. Fig.2B shows typical current voltage 
curves constructed in the absence (vehicle alone) and 
presence of 500 PM cromakalim from a holding poten- 
tial of - 80 mV. It is clear that the degree of inhibition 
of the L-like current produced by cromakalim is depen- 
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Fig.2. Effect of cromakalim on high-threshold Ba *+ currents of NG108-15 cells. A. The traces show Ba*+ currents recorded during 1 s steps from 
a holding potential of - 80 mV to a command potential of + 10 mV in the presence (0) and absence (0) of 500 FM cromakalim. Note that no 
decrease at the peak current (the N-component) but reduction of the long-lasting current (the L-component) at the end of the command pulse was 
observed. B. Current-potential plot of Ba” currents at peak (A, A) and after 1 s (O,O) and during (A ,0) cromakalim application, as indicated. 
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dent on the command potential. The maximal inhibi- 
tion of the L-like current was obtained at potentials 
positive to the threshold potentials (0- + 30 mV), while 
no inhibition in the N-like current was observed in the 
wide range of potentials tested. 
Steady state inactivation curves for 3 components of 
Ca*+ channel currents were obtained by measuring 
Ca*+ and Ba*+ currents at constant command poten- 
tials ( - 40 and 0 mV) from different holding potentials 
(n = 3, each curve). The suppression of the T-like and 
L-like currents was much more obvious at potentials 
more negative than the holding potentials of - 70 mV 
and - 10 mV, respectively, (fig.3A and C), where these 
currents are active. The steady state inactivation curve 
for the N-component was identical in the presence or 
absence of cromakalim (fig.3B). When curves obtained 
in the presence and absence of cromakalim were nor- 
malized, the control and cromakalim curves were 
almost identical (data not shown). These data suggest 
that 3 Ca*+ currents in the presence of cromakalim (i.e. 
the residual current) have time- and voltage-dependent 
inactivation properties similar to the control current. 
The inhibition for T- and L-currents was dose- 
dependent (1C50 = 100 and 102 ,uM, respectively, 
n = 3 and 4) and reversible (data not shown). Since the 
unaffected Ba*+ peak current by cromakalim was in- 
hibited by perfusion of acetylcholine as shown by 
McFadzean et al. [12], the N-like current that was 
measured here was a responsible component. 
The effect of cromakalim on the two components of 
the Ca*+ currents was relatively fast to develop. The in- 
hibition began after a lag period of several seconds, and 
a maximal response was readily obtained within 6.7 min 
after onset of the drug superfusion in 7 cells. 
The suppression of the T-current was confirmed by 
generation of Ca*+ action potentials by constant cur- 
rent stimulation. The peak amplitude of Ca*+ action 
potentials in the presence of 500 ,uM cromakalim was 
smaller than the control value by 47 + 6% (n = 8) 
(data not shown). Furthermore, the tail outward cur- 
rent evoked when 500 ms depolarizing voltage steps 
were stopped, the fast component of afterhyper- 
polarization currents (i.e. Ca*+-activated K+ currents) 
was also suppressed by cromakalim (45 f 6%, 
n = 10). Therefore, these observations indicate that 
Ca*+ influx was depressed by cromakalim. 
The results indicate that cromakalim inhibited T- and 
L-like Ca*+ currents of NG108-15 cells. Although in- 
hibition required a relatively high amount of the drug, 
the ICSO of cromakalim for Ca*+ currents is the same 
order as that for potentiation of the delayed rectifier 
current in hippocampal neurons [13]. Cromakalim did 
not inhibit the N-like Ca*+ current. This implies that 
cromakalim’s action is highly selective, indicating that 
cromakalim may act directly on different Ca*+ channel 
molecules rather than having a non-specific action. 
Taking into account the previous observations that 
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Fig.3. Steady state inactivation curves for 3 components of Ca2+ cur- 
rents constructed in the absence (0) and presence (0) of 500 PM 
cromakalim. Each panel shows T-like Ca*+ currents (A) and the N- 
like(B) or L-like(C) Ba2+ currents. Note that cromakalim reduced the 
amplitude of Ca2+ (A) and Ba*+ (C) currents. Command poten- 
tial = -40 (A) and 0 mV (B and C). 
cromakalim is capable of reducing the slow inward cur- 
rent in the portal vein [5], cromakalim seems to target 
voltage-dependent Ca*+ channels, as well as K+ chan- 
nels [2]. 
In summary, voltage-clamp recordings from neuro- 
blastoma hybrid cells treated with cromakalim enabled 
us to speculate that the drug would impair the Ca*+ cur- 
rents. The results suggest hat blocking the Ca*+ entry 
through the L- and T-type channels may also contribute 
to a cromakalim-induced relaxation of vascular tissues. 
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